Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

Abstract

BackgroundExpression of the long non-coding RNA (lncRNA) LOC285194 was previously shown to be correlated with aggressive clinicopathological features and poor prognosis in several cancers. The aim of the present study was to explore the relationship between LOC285194 expression and clinical outcomes in esophageal squamous cell carcinoma (ESCC), so as to assess whether it could be a novel biomarker for prognosis and prediction of response to therapy on ESCC patients.MethodsThe method of quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure LOC285194 expression in pretreatment biopsy specimens and matched normal tissue derived from ESCC patients who underwent preoperative chemoradiotherapy followed by surgical resection (CRT + S group; n = 55) or from those who received surgical resection alone (S group; n = 87). The association between LOC285194 expression and clinicopathological features and prognosis were then analyzed.ResultsLOC285194 expression was significantly down-regulated in ESCC tumor tissues when compared with the adjacent normal tissues (p < 0.001). Low expression of LOC285194 was associated with larger tumor size (p = 0.002), advanced TNM stage (p = 0.018), more lymph node metastases (p = 0.013) and distant metastases (p = 0.015). In the CRT + S group, the pathological complete response rate was 57% (16/28) for the LOC285194-high group, and 15% (4/27) for the LOC285194-low group. Univariate analysis revealed that low expression of LOC285194 was significantly correlated with CRT response (p = 0.002). Moreover, Kaplan-Meier survival analysis revealed that patients with low expression of LOC285194 had a decreased disease free survival (DFS) (p < 0.001) and overall survival (OS) (p < 0.001). Multivariable analysis further identified low expression of LOC285194 as an independent prognosis factor for CRT response (p = 0.011), DFS (p < 0.001) and OS (p = 0.002).ConclusionDecreased expression of LOC285194 could serve as a molecular marker to predict the clinical outcome of ESCC patients after surgery, and select patients who would benefit from preoperative CRT.

Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets

“…Recent studies showed that Loc285194 was down-regulated in several cancers such as esophageal squamous cell carcinoma, colorectal cancer, and plays key roles in tumor development and progression [101]. Loc285194 is a direct transcription target of p53 [102].…”

Expanding the p53 regulatory network: LncRNAs take up the challenge

“…In the case of LOC285194, which has been found downregulated in several cancer types (Table 1) [62][63][64], it has been proposed it acts as a miRNA sponge, so that the observed antiproliferative effect would be specifically caused by the downregulation of miR-211. This microRNA is known to be important in tumor cell growth, although it can either promote or repress cellular proliferation, depending on the cell type [65,66].…”

Upregulated long non-coding RNA SBF2-AS1 promotes proliferation in esophageal squamous cell carcinoma

“…lncRNAs are involved in every aspect of cellular processes, including cellular development, modulation of apoptosis, metastasis and parental imprinting (8)(9)(10). Emerging evidence suggests that the dysregulation of lncRNAs is linked to the development and metastasis in several types of cancer, including EC (11)(12)(13). The importance of lncRNAs in ESCC carcinogenesis has been recently evidenced.…”